The purpose of this clinical trial is to compare the use of an investigational medicine and lenalidomide vs. lenalidomide alone as maintenance in patients with newly diagnosed multiple myeloma who are minimal residual disease positive after an autologous stem cell transplant.
This trial is currently open and accepting patients.
Participants in this study will be randomly assigned to one of two groups (also called arms). Participants in Arm A will receive daratumumab and lenalidomide, while participants in Arm B will receive lenalidomide alone.
Participants in either arm will receive their therapies in 28 day cycles, and may receive up to 36 cycles as long as their myeloma doesn’t get worse or they don’t experience bad side effects.
ARM A
ARM B
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Phase 3
Enrollment: 214 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Birmingham, AL
Glendale, AZ
Goodyear, AZ
San Francisco, CA
La Jolla, CA
Los Angeles, CA
Denver, CO
Denver, CO
Fort Collins, CO
New Haven, CT
Jacksonville, FL
Miami, FL
Miami, FL
Tampa, FL
Weston, FL
Athens, GA
Niles, IL
Zion, IL
Fort Wayne, IN
Indianapolis, IN
Jefferson, LA
Baltimore, MD
Boston, MA
Detroit, MI
Grand Rapids, MI
Jackson, MS
Kansas City, MO
New Brunswick, NJ
Bronx, NY
Lake Success, NY
Mineola, NY
New York, NY
New York, NY
Syracuse, NY
Chapel Hill, NC
Winston-Salem, NC
Charlotte, NC
Charlotte, NC
Winston-Salem, NC
Cincinnati, OH
Portland, OR
Philadelphia, PA
Pittsburgh, PA
Pittsburgh, PA
West Reading, PA
Boiling Springs, SC
Greenville, SC
Mempis, TN
Nashville, TN
Austin, TX
Dallas, TX
Dallas, TX
Houston, TX
San Antonio, TX
Tyler, TX
Salt Lake City, UT
Fairfax, VA
Charlottesville, VA
Norfolk, VA
Seattle, WA
Seattle, WA
Washington, DC
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
SparkCures is working closely with Janssen Research & Development to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors